{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-105923","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.631103+00:00","generated_at":"2026-05-17T00:36:46.447049+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verastem posts $11.2M Q3 product revenue, GAAP net loss $98.5M","bullets":["AVMAPKI FAKZYNJA CO-PACK achieved $11.2 million net product revenue in first full quarter of launch.","GAAP net loss $98.5M ($1.35/share) vs $24.0M ($0.60) YoY; non-GAAP adjusted net loss $39.4M ($0.54/share).","Cash $137.7M; with product revenue and warrant exercises, runway into H2 2026.","VS-7375 cleared 400 mg and 600 mg QD monotherapy with no DLTs; no nausea/vomiting/diarrhea >Grade 1.","RAMP 301 (LGSOC) completed targeted enrollment of 270 patients early; IDMC recommended 29 additional patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-105923","json":"https://secwatch.observer/filing/0001104659-25-105923.json","markdown":"https://secwatch.observer/filing/0001104659-25-105923.md","text":"https://secwatch.observer/filing/0001104659-25-105923.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/0001104659-25-105923-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:36:46.447049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}